

## NextCell Pharma publishes prospectus supplement

*NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SWITZERLAND, SINGAPORE OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.*

The Board of Directors of NextCell Pharma AB ("NextCell" or the "Company") has prepared a supplement to the prospectus regarding the invitation to subscribe for shares in the Company's resolved rights issue, which was approved by the Swedish Financial Supervisory Authority on 3 December 2020, and published on the same day. The prospectus supplement has been prepared due to the information in the Company's press release on 10 December 2020 regarding results in the Company's continuation study ProTrans-Repeat and the Company's press release on 15 December 2020 regarding the observation study ProTrans-OBS.

The supplement, which today on 16 December 2020 has been approved and registered by the Swedish Financial Supervisory Authority, forms part of and must be read together with, the prospectus. The supplement and the prospectus are available on the Company's website, [www.nextcellpharma.com](http://www.nextcellpharma.com).

Investors who before the publication of the supplement have applied for, or in any other manner consented to, subscription of shares in the rights issue have, under Article 23 of Regulation (EU) 2017/1129 of the European Parliament and of the Council, the right to withdraw their application or consent within two working days from the publication of the supplementary prospectus, i.e., up to and including 18 December 2020. A withdrawal shall be made in writing to Avanza Bank AB, Box 111 93 Stockholm or via e-mail to [corpemissioner@avanza.se](mailto:corpemissioner@avanza.se). Applications that are not withdrawn within the prescribed time will remain binding. No measure is required for investors wishing to withhold their subscription of shares.

### Advisors

Vator Securities AB is financial advisor, and Eversheds Sutherland Advokatbyrå AB is legal advisor to NextCell in connection with the rights issue. Avanza Bank AB is issuing agent in connection with the rights issue.

### For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Sofia Fredrikson, CFO

Tel: 08-735 5595

E-mail: [info@nextcellpharma.com](mailto:info@nextcellpharma.com)

Hemsida: [www.nextcellpharma.com](http://www.nextcellpharma.com)

LinkedIn: <https://www.linkedin.com/company/15255207/>

Twitter: <https://twitter.com/NextCellPharma>

### About NextCell Pharma AB

NextCell is a Phase II cell therapy company with the lead candidate ProTrans™, for the treatment of type-1 diabetes. Focus is to take ProTrans™ to market approval via a phase III study. Furthermore, NextCell operates Cellaviva, Scandinavia's largest stem cell bank for family-saving of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Health and Social Care Inspectorate. FNCA Sweden AB is appointed Certified Adviser, +46(0)8-528 00 399, [info@fnca.se](mailto:info@fnca.se).

### **Important information**

The information in this press release does not constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in NextCell. No action has been taken and measures will not be taken to allow an offer to the public in any jurisdiction other than Sweden. The invitation to interested persons to subscribe for shares in NextCell will only be made through the prospectus.

Neither subscription rights, paid interim shares ("BTA") nor newly issued shares have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTAs or newly issued shares have been registered or will be registered under the United States Securities Act of 1933 in its current wording, or under any other applicable law in the United States, Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore or in any other country where the rights issue or distribution of the press release is contrary to applicable laws or regulations or requires that further prospectuses be prepared, registered or that any other measure is taken in addition to what is required by Swedish law. Accordingly, the press release, as well as the prospectus, the supplement, application form and other documents attributable to the rights issue, may not be distributed to or within any such jurisdiction.

This announcement may include forward-looking statements, which are based on NextCells' current expectations and projections about future events and financial and operational development. Words such as "intends", "will", "expects", "anticipates", "may", "plans", "estimates", and other expressions that imply indications or predictions of future developments or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future performance or development and actual results may differ materially from what is expressed in forward-looking information.

This information, the opinions, and forward-looking statements contained in this announcement, are applies only at this date and are subject to change without notice. NextCell makes no commitments to disclose updates or revisions to forward-looking information, future events or similar circumstances, other than as required by applicable law.